ATE254135T1 - Humaner tumornekrosefaktor delta und epsilon - Google Patents

Humaner tumornekrosefaktor delta und epsilon

Info

Publication number
ATE254135T1
ATE254135T1 AT96910483T AT96910483T ATE254135T1 AT E254135 T1 ATE254135 T1 AT E254135T1 AT 96910483 T AT96910483 T AT 96910483T AT 96910483 T AT96910483 T AT 96910483T AT E254135 T1 ATE254135 T1 AT E254135T1
Authority
AT
Austria
Prior art keywords
epsilon
polypeptides
necrosis factor
tumor necrosis
human tumor
Prior art date
Application number
AT96910483T
Other languages
English (en)
Inventor
Jian Ni
Guo-Liang Yu
Reiner L Gentz
Patrick J Dillon
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE254135T1 publication Critical patent/ATE254135T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96910483T 1996-03-14 1996-03-14 Humaner tumornekrosefaktor delta und epsilon ATE254135T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2247285A CA2247285C (en) 1996-03-14 1996-03-14 Human tumor necrosis factor delta and epsilon
PCT/US1996/003774 WO1997033902A1 (en) 1996-03-14 1996-03-14 Human tumor necrosis factor delta and epsilon
CN96180213A CN1214050A (zh) 1996-03-14 1996-03-14 人肿瘤坏死因子δ和ε

Publications (1)

Publication Number Publication Date
ATE254135T1 true ATE254135T1 (de) 2003-11-15

Family

ID=27170805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910483T ATE254135T1 (de) 1996-03-14 1996-03-14 Humaner tumornekrosefaktor delta und epsilon

Country Status (11)

Country Link
EP (2) EP1362916A3 (de)
JP (1) JP2001501453A (de)
CN (1) CN1214050A (de)
AT (1) ATE254135T1 (de)
AU (1) AU726486C (de)
CA (1) CA2247285C (de)
DE (1) DE69630710T2 (de)
DK (1) DK0897390T3 (de)
ES (1) ES2210354T3 (de)
PT (1) PT897390E (de)
WO (1) WO1997033902A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU3461797A (en) 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Fas ligand-like protein, its production and use
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EE200000147A (et) * 1997-09-12 2001-02-15 Biogen, Incorporated April - uus kasvuefekte omav valk
JP2002516069A (ja) * 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
US6297022B1 (en) * 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
JP2002503444A (ja) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6365369B1 (en) * 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
ES2151403B1 (es) * 1998-07-13 2001-07-01 Hernandez Bronchud Miguel Linea celular transformada de rata productora de tnf-alfa humano recombinante.
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
MXPA02001665A (es) 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1259544B1 (de) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologes polypeptid der tnf familie
ATE329610T1 (de) 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
WO2001096528A2 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP2116259B1 (de) 2001-05-24 2012-01-25 ZymoGenetics, Inc. TACI-Immunoglobulin-Fusionsproteine
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
EP1709072A1 (de) * 2004-01-29 2006-10-11 Genentech, Inc. Varianten der extrazellulären domäne von bcma und verwendungen dafür
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
UA93516C2 (ru) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
NZ572373A (en) 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585690D1 (de) * 1984-12-21 1992-04-23 Biogen Inc Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren.

Also Published As

Publication number Publication date
ES2210354T3 (es) 2004-07-01
EP1362916A2 (de) 2003-11-19
DE69630710T2 (de) 2004-09-23
EP1362916A3 (de) 2004-02-18
EP0897390B1 (de) 2003-11-12
DK0897390T3 (da) 2004-03-08
JP2001501453A (ja) 2001-02-06
CA2247285A1 (en) 1997-09-18
AU726486C (en) 2004-02-05
AU726486B2 (en) 2000-11-09
PT897390E (pt) 2004-03-31
CA2247285C (en) 2011-11-08
WO1997033902A1 (en) 1997-09-18
DE69630710D1 (de) 2003-12-18
EP0897390A4 (de) 1999-04-07
AU5366596A (en) 1997-10-01
CN1214050A (zh) 1999-04-14
EP0897390A1 (de) 1999-02-24

Similar Documents

Publication Publication Date Title
ATE254135T1 (de) Humaner tumornekrosefaktor delta und epsilon
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
EP0825260A3 (de) Arginase II
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
EP0907719A4 (de) Menschliches zytokinpolypeptid
WO2001096528A3 (en) Human tumor necrosis factor delta and epsilon
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2001060990A3 (en) Sphingosine kinases
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002010216A3 (en) Proteins and nucleic acids encoding same
DE60125148D1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2002066643A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002057452A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002026826A3 (en) Proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0897390

Country of ref document: EP